

National Institute for Health and Care Excellence

Final

Kidney Cancer: diagnosis and management

NICE guideline: acknowledgments

NICE guideline NG256

Authors and contributors

March 2026

National Institute for Health and Care Excellence

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and, where appropriate, their carer or guardian.

Local commissioners and providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE 2026. All rights reserved. Subject to [Notice of rights](#).

Contents

1	Guideline developers	5
1.1	Members of the NICE guideline committee:.....	5
1.2	Members of the NICE Guideline Development Team:	5
1.3	Members of the wider NICE Team:	6
1.4	Acknowledgements:	6

1 Guideline developers

1.1 Members of the NICE guideline committee:

Name	Role
Baljit Singh	Chair
Axel Bex	Urological Surgeon
Janet Brown	Medical Oncologist
Lisa Browning	Histopathologist
Amarnath Challapalli	Clinical Oncologist (General)
Amy Clifford	Clinical Oncologist (SABR)
John Connolly	Lay Member
David Cullen	Urology Cancer Nurse
Stuart Evans	Oncology Pharmacist
Geraldine Fox	Lay Member
Fayiza Habeeb	Lead Nurse Practitioner
David Mole	Nephrologist (co-opted member)
Vishal Patil	Anaesthetist (co-opted member)
Ankit Rao	Medical Oncologist
Ana Semedo	Oncology Cancer Nurse / Vice Chair
Sandeep Singh Randhawa	General Practitioner
Grant Stewart	Topic Adviser
Maxine Tran	Urological Surgeon
Tze Min Wah	Interventional Radiologist
James Whitworth	Clinical Geneticist (co-opted member)
Sam Withey	Diagnostic Radiologist
Rose Woodward	Lay Member

1.2 Members of the NICE Guideline Development Team:

Name	Role
Adefisayo Abba-Abba	Technical Analyst
Sarah Boyce	Senior Technical Analyst
Lindsay Claxton	Technical Adviser – Health Economics
Danielle Conroy	Project Manager
Olivia Crane	Senior Technical Analyst
James Hall	Senior Guidance Content Designer
Marie Harrisingh	Topic Lead
Debra Hunter	Project Manager
Kate Kelley	Associate Director
Jonathan Littler	Project Manager
Lina Manounah	Technical Analyst
Yolanda Martinez	Technical Analyst
Sarah Matthews	Technical Analyst

Name	Role
Agnesa Mehmeti	Technical Analyst
Tayyaba Mumtaz	Technical Analyst
Karen Peploe	Senior Technical Analyst - Scoping
Nancy Pursey	Technical Analyst
Steve Sharp	Topic Lead
Hannan Tebbs	Senior Health Economist
Ahmed Yosef	Technical Analyst
Ellie Zachariades	Senior Guidance Content Designer
Fernando Zanghelini	Technical Analyst
Yuanyuan Zhang	Senior Health Economist

1.3 Members of the wider NICE Team:

Name	Role
James Baker	Media Relations Manager
Jeremy Braybrooke	Consultant Clinical Adviser (QA)
Victoria Carter	Implementation Support Manager
Chris Carmona	Technical Adviser (QA)
Sarah Case-Scott	Public Involvement Adviser, People and Communities Involvement and Engagement Team
Amy Finnegan	Senior Information Specialist
Benjamin Gregory	Business Analyst – Resource Impact
Ifigeneia Mavranouzouli	Health Economic Adviser (QA)
Katherine Saxby	Pharmacist Clinical Adviser

1.4 Acknowledgements:

Thanks to Professor Elena Pizzo, Department of Primary Care and Population Health, University College London for providing expert testimony on the cost-effectiveness of MIBI, biopsy or surgery in diagnosing T1 kidney cancer. See [Evidence Review J](#) for further details.

Thanks to NHS England, Getting it Right First Time (GIRFT) and the authors of 'Urology: Towards better care for patients with kidney cancer' for allowing us to reference their work. See [Evidence Review F](#) for further details.